Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Halozyme Therapeutics

Request full access

Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets

San Diego, United StatesFounded 1998Biotech & Life Sciences
Valuation $12B Market cap · Aug/2026
Revenue $1.77B Latest reported FY
EBITDA $891M Latest reported FY

At a glance

Status
Listed
Founded
1998
Headquarters
San Diego, United States
Listing
IPO 2004
Sector
Biotech & Life Sciences
Outcome tier
Decacorn$10B+ valuation tier

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom
Market maps in Biotech & Life Sciences
Market map Rare Disease Therapeutics & Technologies Landscape Market map Digital therapeutics Market map Psychedelic therapeutics
Unicorn lists
Biotech & Life Sciences unicorns Unicorn list Biotech & Life Sciences unicorns Unicorns in United States Unicorn list Unicorns in United States

News

News Halozyme prices upsized $1.3B convertible note offering Sep 18, 2026

Open roles

Track hiring at Halozyme TherapeuticsOpen roles, team growth and hiring by functionBook a demo
Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Halozyme Therapeutics in the San Diego ecosystem

Live from Dealroom

The Halozyme Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Artiman Ventures

Series B and later1 investor entered at this stage

  • Sidney Kimmel Cancer Center

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown
Web traffic by country
9.8K monthly visits
across markets
🇺🇸 United States56.1%
🇨🇦 Canada20.4%
🇨🇭 Switzerland8.2%
🇯🇵 Japan7.1%
🇮🇳 India4.1%
Top 5 markets shown

Patents

Estimated portfolio value
$156M

88 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Halozyme Therapeutics was the backer or acquirer, 2022–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Halozyme Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Halozyme Therapeutics's portfolio, mapped.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Halozyme Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Halozyme Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles